ClinicalTrials.gg
SuspendedNCT05617716SPORTSMENUpdated Nov 18, 2026

Spine Radiosurgery for Symptomatic Metastatic Neoplasms

A Phase 2 interventional study of Conventional external beam radiation therapy dose (EBRT) and Spine radiosurgery/stereotactic body radiation therapy standard dose in Metastatic Neoplasm to the Spine and Metastatic Neoplasm, sponsored by University of Oklahoma. Suspended at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Oklahoma · Phase 2, Interventional, and Treatment

How we know

Why this study was suspended
PI is leaving the institution
Updated Nov 18, 2026Now SuspendedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
262nd of 1,866
240 · median 43
Started
2025
with 84 others
Phase 2
565 of 2,057
58 open now
Registered
1,734th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 262nd largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 85 that started in 2025, is one of 565 in phase 2, and was the 1,734th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare three types of radiation therapy for cancer that has spread to the spine. The two types of radiation therapy used in this trial are External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT). EBRT delivers tightly targeted radiation beams from outside the body. SBRT is a specialized type of radiation therapy that allows high doses of radiation to small targets. This study will include standard dose SBRT and higher dose SBRT. Each participant will be randomly assigned to either EBRT, standard dose SBRT, or higher dose SBRT.

Read the detailed description

Metastatic spine cancer incidence is increasing; the primary treatment is radiation therapy. Metastatic spine disease has been historically treated with external beam radiation therapy (EBRT) with conventional fractionation, yielding relatively limited durability in pain control. The increased lifespan of patients with metastatic cancer has resulted in an increase in the incidence of spine metastases, which has led to a need for more durable treatment results. Stereotactic radiosurgery (SRS)/Stereotactic body radiation therapy (SBRT) of the spine has exponentially increased, with the theoretical advantages of higher tumoricidal dose and more rapid fall off between tumor and surrounding normal tissue compared with EBRT. The goal of this study is to compare three types of radiation therapy to draw conclusions on what is an effective treatment to reduce pain and increase pain freedom rates.

Patients in this trial will be randomized in a 1:1:1 ratio into one of three treatment arms: SBRT (24 Gy in 2 fractions), SBRT (19 Gy in 1 fraction), or conventional EBRT (8 Gy in 1 fraction). Participants will complete three questionnaires-the Brief Pain Inventory, COST-FACIT, and EuroQol EQ-5D-at baseline and again during the 3- to 12-month follow-up period.

03

Conditions studied

  • Metastatic Neoplasm to the Spine
  • Metastatic Neoplasm

Browse trials for

Keywords

  • Radiosurgery
  • External Beam Radiation Therapy
  • Stereotactic Body Radiation Therapy
  • Spine Stereotactic Radiosurgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have histologic confirmation of . Spinal disease must be confirmed by imaging.
  • Participant must have received no prior therapies for this disease. Prior therapy includes previous radiation therapy encompassing the anatomic site to be treated with spine SBRT. This includes any previous radiation therapy where the treatment field overlaps with the anatomic site to be treated with spine SBRT (even if that previous radiation therapy was not for treatment of spinal disease). Systemic radiation therapy for metastatic disease such as Pluvicto also counts as previous radiation therapy.
  • Age >18 years. This study requires by the participant; as children are not able to perform this without parental approval, Participant \< age 18 are excluded from this study.
  • of≥ 3 months, in the opinion of and as documented by the investigator.
  • Participant must have a worst pain score \< 2 of 10 according to the Brief Pain Inventory
  • Participant must have no intention of changing pain medications on the first day of SBRT
  • Participant must have a Spinal Instability score (SINS) ≤ 12
  • Participant must be a spine SBRT candidate per Radiation Oncology
  • Participant must have the ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Exclusion Criteria:

  • Participant receiving any other agents.
  • Participant with prognosis less than 3 months will be excluded from this clinical trial because of their poor prognosis and decreased likelihood to meet the primary endpoint
  • Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing Participant are excluded due to toxicity of radiation therapy.
  • Participant is unable to receive MRI of the spine
  • Participant has a Spinal Instability in Neoplasia score (SINS) ≥ 12
  • Participant has received previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field
  • Participant has more than 3 consecutive vertebral bodies in the SBRT treatment volume
  • Participant is not an SBRT candidate per radiation oncology discretion
  • Participant has a known primary and has an estimated median survival≤ 3 months
  • Participant has an unknown primary
  • Participant has a Brief Pain Inventory score > 2
  • Participant has received previous radiation therapy involving the intended SBRT treatment field
  • Participant has received previous spinal surgical procedure involving the SBRT target volume. is not considered a previous spinal surgical procedure.
  • Participant has neurological deficits from malignant cauda equina compression or epidural spinal cord compression
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Standard SBRT

    Participants will undergo standard dose Stereotactic Body Radiation Therapy as part of standard of care.

    Radiation: Spine radiosurgery/stereotactic body radiation therapy standard dose

  • Experimental
    High Dose SBRT (SOC)

    Participants will undergo high dose Stereotactic Body Radiation Therapy as part of standard of care.

    Radiation: Spine radiosurgery/stereotactic body radiation therapy high dose

  • Experimental
    Conventional EBRT (SOC)

    Participants will undergo External Beam Radiation Therapy as part of standard of care.

    Radiation: Conventional external beam radiation therapy dose (EBRT)

Interventions

  • RadiationConventional external beam radiation therapy dose (EBRT)

    Participants will undergo 8 Gray in 1 fraction of EBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.

  • RadiationSpine radiosurgery/stereotactic body radiation therapy standard dose

    Participants will undergo 24 Gray in 2 fractions of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.

  • RadiationSpine radiosurgery/stereotactic body radiation therapy high dose

    Participants will undergo 19 Gray in 1 fraction of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.

06

What researchers measure

Primary outcomes

  1. Proportion of patients who experience 3-month pain freedom based on BPI score

    Freedom from pain at 3 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI.

    Time frame: 3 months

Secondary outcomes

  1. Proportion of patients who experienced 6-month pain freedom based on the BPI score

    Freedom from pain at 6 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI.

    Time frame: 6 months

  2. Local control actuarial rate at 6-months

    6-month local control, defined as an actuarial 6-month rate of any new, recurrent or progressing (as defined by SPINOcriteria) tumor within the planning target volume on any post-treatment MRI by 6 months. Follow-up MRIs will be fused with the planning scan for this assessment

    Time frame: 6 months

  3. Vertebral compression fracture rate at 6-months

    6-month vertebral compression fracture rate, assessed by post-treatment MRI by 6 months

    Time frame: 6 months

  4. Proportion of patients who experienced progression-free survival

    Overall participant survival

    Time frame: 6 months

  5. Vertebral compression fracture rate at 12-months

    12-month vertebral compression fracture rate, assessed by post-treatment MRI at 12 months

    Time frame: 12 months

  6. Perceived demographic disparities in patients at 3-month follow-up

    Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 3 months

    Time frame: 3 months

  7. Perceived demographic disparities in patients at 6-month follow-up

    Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 6 months

    Time frame: 6 months

07

Study locations

2 sites
  • Johns Hopkins University Hospitals
    Baltimore, Maryland 21287, United States
  • OU Health Stephenson Cancer Center
    Oklahoma City, Oklahoma 73117, United States
08

References and documents

Publications

  • Oboh EC, Anwar M, Perry L, Cleaver N, McClelland S 3rd. Early Economic and Patient-Centered Outcomes Before Spine Metastases Radiation Therapy From an Ongoing Phase II Randomized Controlled Trial. Am J Clin Oncol. 2026 Jun 16. doi: 10.1097/COC.0000000000001346. Online ahead of print. PubMed 42302152 ↗
  • Gardner UG Jr, Brawley OW, Obi EE, Redmond KJ, McClelland S 3rd. Establishing a Protocol to Increase Racial/Ethnic Under-Represented Minority Enrollment on an Active Radiation Oncology Multicenter Randomized Clinical Trial. Am J Clin Oncol. 2025 Jun 1;48(6):310-313. doi: 10.1097/COC.0000000000001174. Epub 2025 Feb 11. PubMed 39930584 ↗
  • McClelland S 3rd, Sun Y, Spratt DE. Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN): a randomized phase II study protocol. Rep Pract Oncol Radiother. 2023 Jul 25;28(3):379-388. doi: 10.5603/RPOR.a2023.0037. eCollection 2023. PubMed 37795393 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2025 to primary completion in Oct 2026, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Sep 2028 → Oct 2026 and completion Sep 2029 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 15, 2022
StartActual
Sep 9, 2025
Primary completionActual
Oct 5, 2026was Sep 2028
CompletionEst.
Oct 5, 2027was Sep 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended PI is leaving the institution
changed Nov 18, 2026
Primary completion
Sep 30, 2028→Oct 5, 2026 (actual)
Nov 18, 2026
Study completion
Sep 30, 2029→Oct 5, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Suspended
    Why stopped PI is leaving the institution
    Primary completion Sep 30, 2028→Oct 5, 2026 (now actual)
    Study completion Sep 30, 2029→Oct 5, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05617716
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Sep 9, 2025
Primary completion
Oct 5, 2026
Completion
Oct 5, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Shearwood McClelland III, MD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion